Goldman Sachs Just Delivered Bad News for U.S. Investors ... Sort Of. Here's What You Need to Know.

Goldman Sachs projects the S&P 500 will return about 6.5% annually over the next decade (versus a long‑term ~10%), driven by lofty valuations (trailing P/E near 23) and concentration in AI-leading mega caps whose eventual valuation unwind could subtract roughly 1 percentage point per year through 2035, while higher-for-longer rates and limited tax tailwinds constrain margin expansion. To overcome this headwind Goldman recommends strategic tilts away from U.S. mega-cap darlings toward higher-expected regions (Japan ~8.2%, rest of Asia ~10.3%, emerging markets ~10.9% through 2035) and select stocks such as Alibaba and MercadoLibre, noting a roughly 15% overvalued dollar that could add about 2 percentage points annually to foreign returns as currencies reflate. The bank also highlights dividends as a meaningful component of total returns, flagging defensive, high‑yield names like Coca‑Cola, Pfizer and Merck (which it says still has substantial pipeline upside) while noting its outlook is a forecast that could change with new data.

Analysis

Goldman Sachs projects the S&P 500 will average about 6.5% annual returns over the next decade versus a long‑term ~10% pace, driven by elevated valuations (trailing P/E near 23) and concentration in AI leaders whose eventual valuation unwind could subtract roughly 1 percentage point per year through 2035. The firm cites diminished margin tailwinds because prior gains were supported by falling interest rates and lower corporate tax burdens—factors unlikely to replicate in the coming decade, which constrains U.S. index upside.

Goldman recommends strategic geographic tilts: Japan (8.2%), rest of Asia (10.3%) and emerging markets (10.9%) through 2035, led by raw earnings growth and a potential ~2 percentage‑point annual boost from a roughly 15% overvalued dollar reversion. It highlights specific foreign opportunities—Alibaba’s pivot to AI and an in‑house AI chip competitive with Nvidia, and MercadoLibre’s 39% top‑line growth (49% constant‑currency) for the quarter to September—as examples of non‑U.S. sources of outperformance.

The report also flags dividends as a meaningful share of total returns across regions, endorsing defensive/high‑yield names such as Coca‑Cola, Pfizer and Merck; Goldman notes Merck’s pipeline could produce up to $50 billion of annual revenue by the mid‑2030s even as Keytruda faces patent erosion beginning 2028. The overall guidance is adaptive reallocation rather than a market exit given persistent structural shifts in rates, FX and AI leadership.

Key Decisions for Investors

• Trim or rebalance U.S. mega‑cap, AI‑heavy positions to reduce exposure to a potential multi‑year valuation re‑rating that Goldman says could subtract ~1% annually through 2035
• Increase targeted exposure to Japan, broader Asia and emerging‑market equities via regional ETFs or high‑quality ADRs (examples cited: BABA, MELI) to capture projected earnings growth and an estimated ~2pp/year FX tailwind as the dollar normalizes
• Add high‑quality dividend payers such as KO, PFE and MRK for income and downside protection, noting Merck’s stated pipeline potential of up to $50bn by the mid‑2030s despite Keytruda patent pressures in 2028
• Monitor macro triggers—aggregate S&P 500 P/E compression, Fed interest‑rate trajectory and dispersion between AI leaders and the rest of the market—as explicit signals to rebalance back into U.S. large caps
• Favor tactical hedges or option overlays rather than wholesale market exits to manage downside while remaining invested and able to capture regionally driven upside